fda glp-1 compounding warning october 2025 Drug Recalls and Warnings: Recalls for Compounded Semaglutide and Tirzepatide, Wegovy; Facility Letters Did the FDA Ban Compounded

In fact, intolerable side effects are among the top reasons cited for discontinuing GLP-1 meds

These compounded preparations are subject to different regulatory standards than FDA-approved manufactured drugs

The main index comparison result of the product of the invention and the commercial product (1) Related substances Sample preparation: pilot samples (production lot: P-110201), process verification samples (production lot: YJ110401, YJ110402, and YJ110403), and commercial products (production lot: 31002)

The GLP-1 trade is broadening, and the opportunity set looks wider than at any point in the last twelve months